US2007054398A1PendingUtilityA1

Human salivary gland-origin stem cell

Assignee: FUMIO ENDOPriority: Feb 20, 2003Filed: Feb 20, 2004Published: Mar 8, 2007
Est. expiryFeb 20, 2023(expired)· nominal 20-yr term from priority
C12N 2506/098A61K 35/12C12N 5/0607C12N 2501/335C12N 2501/119C12N 5/0633C12N 5/00C12N 5/0672C12N 2501/16C12N 2501/235C12N 2501/11C12N 5/0676C12N 5/0678C12N 2501/115
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A novel human stem cell which can be differentiated to cells constituting a plurality of human organs including human liver is disclosed. The human stem cell according to the present invention is originated from human salivary gland, which is CD49f-positive, and which can be differentiated to (1) a nestin-positive and albumin-positive cell, (2) an insulin-positive cell and (3) a glucagon-positive cell by culture in vitro.

Claims

exact text as granted — not AI-modified
1 . An isolated human stem cell originated from human salivary gland, which is CD49f-positive, and which can be differentiated to (1) a nestin-positive and albumin-positive cell, (2) an insulin-positive cell and (3) a glucagon-positive cell by culture in vitro.  
     
     
         2 . A human stem cell which is nestin-positive and albumin-positive, which is induced by culturing a human salivary gland cell in vitro, and which can be differentiated to an insulin-positive cell and a glucagon-positive cell by culture in vitro.  
     
     
         3 . An insulin-positive cell induced by culturing said human stem cell according to  claim 2  in vitro.  
     
     
         4 . A glucagon-positive cell induced by culturing said human stem cell according to  claim 2  in vitro.  
     
     
         5 . The cell according to any one of  claims 1  to  4 , which is originated from an adult.  
     
     
         6 . A method for obtaining human stem cells, comprising collecting CD49f-positive cells from cells originated from human salivary gland tissue, and culturing the cells in the presence of epidermal growth factor to induce human stem cells originated from human salivary gland, which are CD49f-positive, and which can be differentiated to (1) nestin-positive and albumin-positive cells, (2) insulin-positive cells and (3) glucagon-positive cells by culture in vitro, and collecting the induced human stem cells.  
     
     
         7 . A method for obtaining human stem cells, comprising culturing in vitro, in the presence of fibroblast growth factor, epidermal growth factor and leukemia inhibitory factor, human stem cells originated from human salivary gland, which are CD49f-positive, and which can be differentiated to (1) nestin-positive and albumin-positive cells, (2) insulin-positive cells and (3) glucagon-positive cells by culture in vitro, to induce nestin-positive and albumin-positive cells, and collecting the induced nestin-positive and albumin-positive cells.  
     
     
         8 . A method for obtaining insulin-positive cells, comprising culturing in vitro human stem cells which are nestin-positive and albumin-positive, which are induced by culturing human salivary gland cells in vitro, and which can be differentiated to insulin-positive cells and glucagon-positive cells by culture in vitro to induce insulin-positive cells, and collecting the induced insulin-positive cells.  
     
     
         9 . A method for obtaining glucagon-positive cells, comprising culturing in vitro human stem cells which are nestin-positive and albumin-positive, which are induced by culturing human salivary gland cells in vitro, and which can be differentiated to insulin-positive cells and glucagon-positive cells by culture in vitro to induce glucagon-positive cells, and collecting the induced glucagon-positive cells.  
     
     
         10 . The method according to  claim 8  or  9 , wherein said culturing in vitro is carried out by spheroid culture.

Join the waitlist — get patent alerts

Track US2007054398A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.